NCT00090675View on ClinicalTrials.gov

Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG

ZD1839

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY

NCT00090675 - Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter